Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Cipla
Chinese Patent Office
Teva
Baxter
Argus Health
UBS
Cantor Fitzgerald

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,858,789

« Back to Dashboard

Which drugs does patent 7,858,789 protect, and when does it expire?

Patent 7,858,789 protects NUPLAZID and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.
Summary for Patent: 7,858,789
Title:Derivatives of 4-aminopiperidine and their use as a medicament
Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula ##STR00001## in which R.sub.1, R.sub.2 and R.sub.3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
Inventor(s): Thurieau; Christophe (Paris, FR), Gonzalez; Jerome (Annemasse, FR), Moinet; Christophe (Montreal, CA)
Assignee: Ipsen Pharma S.A.S. (Boulogne-Billancourt, FR)
Application Number:12/151,115
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,858,789

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,858,789

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 15724Dec 14, 1999

Non-Orange Book US Patents Family Members for Patent 7,858,789

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,110,574 Derivatives of 4-aminopiperidine and their use as a medicament ➤ Sign Up
7,115,634 4-aminopiperidine and their use as a medicine ➤ Sign Up
7,393,861 Derivatives of 4-aminopiperidine and their use as a medicament ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Healthtrust
Federal Trade Commission
Harvard Business School
McKesson
McKinsey
Colorcon
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.